Fig. 4From: A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementiaAnalyses for the change in primary and secondary outcomes from baseline to week 36. *The direction of the ADCS-ADL change scores was reversed for consistency with the other outcomesBack to article page